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ABSTRACT
Patients with mantle cell lymphoma (MCL) usually respond to initial combination chemotherapy,
but the disease inevitably relapses and often follows an aggressive course. Here, clinical study
results published since 2008 for patients with relapsed/refractory MCL were reviewed to compare
available evidence for treatment guidance. Most trials identified were non-randomized, phase II
studies performed at a limited number of sites, and many evaluated MCL as one of multiple
non-Hodgkin lymphoma subtypes. Additional randomized, comparative trials are needed.
Treatment selection generally depends on patient need, age and fitness, time of relapse, and
line of therapy. Combination regimens typically produce higher response rates than single
agents, and adding rituximab generally improves outcomes. The inclusion of ibrutinib, lenalido-
mide, temsirolimus, and bortezomib, represents an important advance for patients ineligible for,
unable to tolerate, or failing high-intensity combination chemotherapy. A high need for effective
treatments in relapsed/refractory MCL remains, particularly for elderly and frail patients.
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Introduction
Mantle cell lymphoma (MCL) is a distinct histologic
type of non-Hodgkin lymphoma (NHL), with a median
age of 65 years at diagnosis and predominantly more
aggressive course of disease [1,2]. Diagnosis is based
on morphology and immunophenotype (CD20þ,
CD5þ, CD23–, and FMC7þ), but detection of chromo-
somal translocation t(11;14)(q13;q32) or the resulting
cyclin D1 overexpression is mandatory [3,4]. Although
technically categorized as an indolent form of NHL,
MCL typically follows an aggressive clinical course and
is considered incurable. The majority of patients
receive treatment upon diagnosis, except for a small
fraction of patients with very indolent disease identifi-
able by gene expression profiling [5,6] or low-risk char-
acteristics and/or evolution of disease [7,8].
Median overall survival (OS) following initial induc-
tion therapy is 3–5 years with the use of dose-intense
chemotherapy or combination therapy, incorporation
of antilymphoma antibodies, and autologous stem cell
transplantation [1,2,9–11]. US guidelines issued by the
National Comprehensive Cancer NetworkVR (NCCNVR )
categorize induction based on aggressive versus less
aggressive treatment [12], whereas the European (EU)
guidelines categorize induction based on the patient’s
age (<65 versus 65 years) and status (fit versus frail)
[1,2,13]. Aggressive treatment in the US guidelines and
treatment of fit patients 65 years of age in EU guide-
lines consist of high-dose chemoimmunotherapy fol-
lowed by consolidation with high-dose therapy and
autologous stem cell transplantation. R-hyperCVAD (rit-
uximab combined with hyperfractionated cyclophos-
phamide, vincristine, doxorubicin, and dexamethasone
alternating with high-dose methotrexate and cytara-
bine) is also recommended as an aggressive regimen
in US but not EU guidelines. Less aggressive treatment
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in the US and treatment of fit, elderly patients in the
EU consist of a conventional regimen such as R-CHOP
(rituximab, cyclophosphamide, doxorubicin, vincristine,
and prednisone) or BR (bendamustine and rituximab).
Although MCL generally responds to initial treat-
ment, the disease inevitably relapses, even after an
intensive intervention [14]. Treatment of relapsed or
refractory disease, characterized by increasingly shorter
periods of remission with successive lines of treatment
and progression to more clinically aggressive pheno-
type, is challenging [1,2,14,15]. This review covers cur-
rent treatment options in the relapsed/refractory
setting, examining selection based on prior therapy,
patient characteristics, performance status, and line of
therapy. Conventional chemotherapy approaches as
well as newer molecular-based therapies are included.
Methods
A review of the literature was carried out using
PubMed to identify studies reporting clinical trial
results in patients with relapsed/refractory MCL pub-
lished between January 2008 and July 2017. Search
terms included: title mantle cell lymphoma, publication
type clinical trial, and language English. Abstracts from
major conferences (American Society of Clinical
Oncology [ASCO], American Society of Hematology
[ASH], European Hematology Association [EHA], and
International Conference on Malignant Lymphoma
[ICML]) were also evaluated. Trials in previously
untreated MCL patients, those with <10 MCL patients,
pharmacokinetic studies, and publications such as let-
ters to the editor were excluded, and the resulting list
was focused on studies of key marketed and investiga-
tional agents. Studies were categorized as monother-
apy, chemotherapy/chemoimmunotherapy,
chemotherapy/immunotherapy combinations with
molecular-based agents, and combination biologic
therapies.
Study data
Chemoimmunotherapy
Chemoimmunotherapy trials in relapsed/refractory
MCL are shown in Table 1, with key results discussed
below [16–26]. Many recommendations regarding use
of chemoimmunotherapy to treat relapsed/refractory
MCL are based on limited studies and few randomized
comparative trials. The most commonly used combina-
tions in this setting are CHOP and regimens containing
bendamustine, cytarabine, or fludarabine in combin-
ation with rituximab. The addition of rituximab to
chemotherapy regimens has shown improved OS [27].
These combination regimens tend to be more appro-
priate in first and second relapse in younger patients
and elderly fit patients. While they appear to produce
higher response rates than monotherapy, few compari-
sons have been made in randomized trials.
The alkylating agent bendamustine in combination
with rituximab (BR regimen) has high activity in
relapsed/refractory MCL [28]. Phase II findings with BR
within this time period showed 92% overall response
rate (ORR), 55% complete response (CR)/CR uncon-
firmed (CRu), and median duration of response (DOR)
of 19 months in relapsed/refractory MCL [17].
Subsequent studies of BR showed significantly pro-
longed progression-free survival (PFS), producing a sig-
nificantly higher ORR compared with fludarabine plus
rituximab (FR) in a phase III study conducted in
patients with relapsed follicular, indolent, and mantle
cell lymphomas [18]. Among MCL patients who were
randomized to BR or FR, ORR was 71% (38% CR) and
26% (13% CR), respectively, and median PFS was 17.6
and 4.7 months, respectively (p¼ .01). BR was also
associated with improved OS (median 35.3 versus 20.9
months). Among all patients treated with BR, the most
common grade 3/4 adverse events (AEs) were leuko-
penia (13%), neutropenia (9%), and nausea and emesis
(4%). In a phase II study with relapsed or refractory
MCL (median 2 prior therapies), BR treatment resulted
in an 82% ORR (40% CR), median PFS of 17.2 months,
and a 3-year OS rate of 55% [19]. Among patients
evaluated by positron emission tomography (PET)
scan, complete metabolic response was observed in
75%. Grade 3/4 neutropenia and lymphopenia
occurred in 44 and 89% of patients, respectively.
Serious AEs occurred in 40% of patients, but only
three patients withdrew from the study due to AEs.
The use of BR in the treatment of relapsed/refractory
MCL has increased steadily based on recent results
from the multicenter, randomized, phase III non-infer-
iority StiL and BRIGHT studies, which reported signifi-
cantly prolonged PFS and CR rates, respectively, in
comparison to R-CHOP or R-CVP (rituximab, cyclophos-
phamide, vincristine, and prednisone), in the small
subsets of previously untreated MCL [29–32].
Novel monotherapy treatment options for
relapsed/refractory MCL
Pivotal trials of monotherapy options in relapsed/
refractory MCL are shown in Table 2 and results from
key studies are discussed below [33–54]. Multiple
treatment options are available in this setting, but no
clear standard of care is recognized in EU or US
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treatment guidelines [1,2,12], ibrutinib, lenalidomide,
and temsirolimus are approved in the EU [55–57],
whereas three molecular-based agents are approved
by the US Food and Drug Administration: ibrutinib
[58], lenalidomide [59], and bortezomib [60].
Ibrutinib, an inhibitor of Bruton’s tyrosine kinase
(BTK), has been approved by the European Medicines
Agency (EMA) for the treatment of adult patients with
relapsed or refractory MCL and in the US for patients
with MCL who have received at least one prior therapy
[56,58]. Ibrutinib was evaluated in a phase II trial
involving MCL patients with a median of three prior
regimens [33,34]. ORR and CR rates improved over
time on therapy, reaching 68 and 21%, respectively.
For the entire cohort, median PFS was 13.9 months
and median OS was not reached. Response rates did
not differ between bortezomib-naïve versus pre-
treated patients, although trends toward longer DOR
and PFS were observed in patients who had received
prior bortezomib. The most common grade 3/4 toxic-
ities were neutropenia (16%) and thrombocytopenia
(11%). The activity of ibrutinib in patients with MCL
progressing after bortezomib therapy was confirmed
in another phase II trial [61].
Both primary and secondary resistance to ibrutinib
in relapsed/refractory MCL has been observed [33].
Two separate retrospective reviews reported poor out-
comes for patients with ibrutinib-resistant MCL after
subsequent salvage therapy, with a median OS of 5.8
[62] and 8.4 months [63] after ibrutinib cessation.
Effective therapy for patients with relapsed MCL with
ibrutinib resistance therefore represents an important
unmet medical need.
Multiple phase II studies have been conducted with
lenalidomide alone and in combination with rituximab
(R2 regimen) [35–42,64]. The pivotal phase II MCL-001
(EMERGE) study in the US established the activity of
lenalidomide in relapsed/refractory MCL, including
patients who received prior bortezomib (median 4
prior regimens) [35]. Lenalidomide provided an ORR of
28% (8% CR/CRu) by independent central review, with
a median DOR of 16.6 months. Median PFS was 4.0
months, and median OS (longer-term follow-up) was
20.9 months [36]. The most common grade 3/4 toxic-
ities were neutropenia (43%) and thrombocytopenia
(27%).
In the phase II, multicenter, open-label MCL-002
(SPRINT) pivotal trial in the EU, patients with relapsed
or refractory MCL were randomized 2:1 to lenalido-
mide monotherapy or investigator’s choice (IC) mono-
therapy (rituximab, gemcitabine, fludarabine,
chlorambucil, or cytarabine) [37]. At a median follow-
up of 15.9 months, lenalidomide significantly improvedTa
bl
e
2.
Co
nt
in
ue
d
Tr
ea
tm
en
t
Ph
as
e
N
o.
of
po
in
ts
Pr
io
r
re
gi
m
en
s,
m
ed
ia
n
(r
an
ge
)
O
RR
(C
R/
CR
u)
M
ed
ia
n
D
O
R,
m
on
th
s
M
ed
ia
n
PF
S/
O
S,
m
on
th
s
M
os
t
Co
m
m
on
G
ra
de
3
AE
s
Bo
rt
ez
om
ib
[5
0,
51
]
II
40
;3
6
ev
al
ua
bl
e
2
(0
–4
)
50
%
(1
7%
)
3.
8
5.
3/
no
t
re
po
rt
ed
Ly
m
ph
op
en
ia
(3
5%
),
th
ro
m
bo
cy
to
pe
ni
a
(3
0%
),
ne
ut
ro
pe
ni
a
(2
0%
),
hy
po
ca
lc
em
ia
(1
3%
)
Bo
rt
ez
om
ib
[5
2]
II
10
N
ot
re
po
rt
ed
25
%
(0
)
6.
7a
6.
7a
Ly
m
ph
op
en
ia
(3
5%
),
ne
ut
ro
pe
ni
a
(1
5%
),
le
uk
op
en
ia
(1
2%
),
an
em
ia
(8
%
),
le
uk
o-
pe
ni
a
(8
%
)
O
th
er
O
bi
nu
tu
zu
m
ab
[5
3]
II
15
3
(1
–1
7)
a
27
%
(1
3%
)
N
ot
re
po
rt
ed
2.
7a
/n
ot
re
po
rt
ed
Ly
m
ph
op
en
ia
(1
5%
),
an
em
ia
(1
0%
),
in
fu
-
si
on
-r
el
at
ed
re
ac
tio
n
(8
%
),
th
ro
m
bo
cy
to
-
pe
ni
a
(8
%
)a
Id
el
al
is
ib
[5
4]
I
40
4
(1
–1
4)
40
%
(5
%
)
2.
7
3.
7/
no
t
re
po
rt
ed
AL
T
in
cr
ea
se
d
(2
0%
),
di
ar
rh
ea
(1
8%
),
AS
T
in
cr
ea
se
d
(1
5%
),
an
or
ex
ia
(1
5%
),
pn
eu
-
m
on
ia
(1
3%
)
SA
Es
:p
ne
um
on
ia
(1
0%
),
di
ar
rh
ea
(8
%
),
ac
ut
e
re
na
lf
ai
lu
re
(5
%
),
pu
lm
on
ar
y
em
bo
lis
m
(5
%
),
py
re
xi
a
(5
%
)
AE
:a
dv
er
se
ev
en
t;
AL
T:
al
an
in
e
am
in
ot
ra
ns
fe
ra
se
;C
R:
co
m
pl
et
e
re
sp
on
se
;C
Ru
:u
nc
on
fir
m
ed
co
m
pl
et
e
re
sp
on
se
;D
O
R:
du
ra
tio
n
of
re
sp
on
se
;I
C:
in
ve
st
ig
at
or
’s
ch
oi
ce
of
rit
ux
im
ab
:g
em
ci
ta
bi
ne
:f
lu
da
ra
bi
ne
:c
hl
or
am
bu
-
ci
l:
or
cy
ta
ra
bi
ne
m
on
ot
he
ra
py
;M
CL
:m
an
tle
ce
ll
ly
m
ph
om
a;
O
RR
:o
ve
ra
ll
re
sp
on
se
ra
te
;O
S:
ov
er
al
l
su
rv
iv
al
;R
/R
:r
el
ap
se
d/
re
fr
ac
to
ry
;P
FS
:p
ro
gr
es
si
on
-f
re
e
su
rv
iv
al
;S
AE
:s
er
io
us
AE
:S
PM
:s
ec
on
d
pr
im
ar
y
m
al
ig
na
nc
y;
TF
R:
tu
m
or
fla
re
re
ac
tio
n;
VO
D
:v
en
o-
oc
cl
us
iv
e
di
se
as
e.
a T
he
se
tr
ia
ls
al
so
in
cl
ud
ed
pa
tie
nt
s
w
ith
ot
he
r
N
H
L
su
bc
la
ss
es
(o
r
oc
ca
si
on
al
ly
ot
he
r
he
m
at
ol
og
ic
al
m
al
ig
na
nc
ie
s)
;d
at
a
m
ar
ke
d
by
as
te
ris
k
ar
e
fo
r
al
lp
at
ie
nt
s
in
th
e
st
ud
y,
ra
th
er
th
an
th
e
su
bs
et
of
M
CL
pa
tie
nt
s.
b
D
at
a
w
er
e
re
po
rt
ed
in
ab
st
ra
ct
fo
rm
.
1818 M. DREYLING ET AL.
PFS compared with IC (median 8.7 versus 5.2 months,
p¼ .004). ORR was 40% (5% CR/CRu) for lenalidomide
and 11% (0% CR/CRu) for IC. Median OS (27.9 versus
21.2 months) also favored lenalidomide. The most
common grade 3 or 4 AEs were neutropenia (44% ver-
sus 34%) without increased risk of infection, thrombo-
cytopenia (18% versus 28%), leukopenia (8% versus
11%), and anemia (8% versus 7%) in the lenalidomide
and IC groups, respectively. Analysis of subgroups and
regression analyzes associated superior PFS with lenali-
domide over IC therapy irrespective of prior treatment
history [65].
Temsirolimus, an mTOR inhibitor, was the first agent
registered by the EMA for relapsed/refractory MCL
[55]. In a pivotal phase III study, temsirolimus was
compared with investigator’s choice of therapy in 162
patients with relapsed/refractory MCL who had
received a median of three prior regimens [43].
Temsirolimus was administered at a dose of 175mg
weekly for 3 weeks followed by either 75 or 25mg
weekly. In the control arm, the investigators selected
from prospectively approved options, most commonly
gemcitabine and fludarabine. Patients receiving the
higher dose of temsirolimus had significantly longer
PFS than those in the investigator’s choice arm (4.8
versus 1.9 months; p¼ .0009); median OS did not differ
significantly (12.8 versus 9.7 months; p¼ .35). The
most frequent grade 3/4 toxicities with the higher
dose of temsirolimus were thrombocytopenia (59%),
anemia (20%), neutropenia (15%), and asthenia (13%).
When patients were retrospectively classified accord-
ing to the MCL International Prognostic Index, a vali-
dated predictor of survival [66], the higher
temsirolimus dose increased PFS by 7.9, 2.8, and 1.1
months compared with investigator’s choice therapy
in low-, intermediate-, and high-risk groups,
respectively.
An international, randomized, open-label, phase III
study compared ibrutinib with temsirolimus in patients
with relapsed or refractory MCL [46,47]. Temsirolimus
was administered at a dose of 175mg weekly for 3
weeks followed by 75mg weekly. At a median follow-
up of 39 months, ORR was significantly improved in
the ibrutinib group (77% versus 47%, p< .0001), as
was PFS (15.6 versus 6.2 months, p< .0001) [47].
Ibrutinib was better tolerated, with lower rates of
grade 3 or 4 thrombocytopenia (9% versus 42%),
anemia (8% versus 20%), neutropenia (13% versus
17%), and fatigue (4% versus 7%) than temsirolimus,
with fewer AEs leading to discontinuation (6% versus
26%) [46]. Major bleeding was more frequent in the
ibrutinib group (10% versus 6%), but after adjusting
for longer ibrutinib exposure, event rates were similar.
In the pivotal phase II PINNACLE study, the prote-
asome inhibitor bortezomib was evaluated in patients
with relapsed MCL who had received a median of one
prior regimen [48]. ORR was 32% and included 8%
with CR/CRu [49]. Median PFS was 6.5 months for all
patients and median OS was 23.5 months. Toxicity was
generally manageable; grade 3/4 lymphopenia
occurred in 34% of patients. The most common grade
3/4 non-hematologic toxicity was peripheral neur-
opathy (13%). Four deaths occurred within 28 days of
the last dose of bortezomib that were probably attrib-
utable to study drug (3 due to non-neutropenic sepsis,
1 due to respiratory failure).
Several newer investigational agents are note-
worthy, and although clinical data are limited, they
show promise for use in combination with other
agents based on their mechanism(s) of action.
Obinutuzumab (GA101) is a glycoengineered human-
ized anti-CD20 monoclonal antibody that exhibited
superior activity compared with rituximab in MCL
xenograft models [67]. In the phase II GAUGUIN study,
obinutuzumab was administered in a subset of MCL
patients [53]. Two different dosing regimens were eval-
uated: 1600mg on days 1 and 8 of cycle 1 and
800mg on day 1 of cycles 2–8, or 400mg at all infu-
sions. Best ORR with obinutuzumab for MCL patients
was 4/15 (27%), with 2/15 (13%) reaching a CR/CRu
and including response durations ranging from 5.5 to
30.5þmonths. Obinutuzumab exhibited an acceptable
safety profile for all patients; grade 3/4 infusion-related
reactions occurred in 3 (8%). Obinutuzumab may rep-
resent an alternative to rituximab as a future option in
combination therapies.
Idelalisib acts via the B-cell receptor (BCR) pathway
and is a selective inhibitor of phosphatidylinositol 3-
kinase delta isoform (PI3Kd). In a phase I study,
patients with relapsed or refractory MCL (median 4
prior treatments) were treated with 50–350mg oral
idelalisib once or twice daily [54]. ORR was 40% (5%
CR), and median PFS was 3.7 months (1-year PFS 22%).
The most frequent grade 3/4 AEs were increased ala-
nine aminotransferase (ALT; 20%), diarrhea (18%),
increased aspartate aminotransferase (AST; 15%), and
anorexia (15%), with 18% of patients discontinuing
due to AEs. Due to limited efficacy, potential toxicity,
and the availability of other targeted agents, the
future of idelalisib in MCL is doubtful.
Venetoclax (ABT-199), a selective inhibitor of the
anti-apoptotic protein BCL-2, received accelerated
approval in the US as monotherapy for patients with
chronic lymphocytic leukemia with 17p deletion and
at least one prior therapy [68], based on results of an
uncontrolled phase II study [69]. Although based on a
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small number of patients, this agent also showed a
very high rate of response (75%) in relapsed/refractory
MCL, comparable to the efficacy of BTK inhibitors, and
would be an attractive option for this group of
patients [70].
Novel agents combined with
chemoimmunotherapy
The addition of molecular-based agents such as ibruti-
nib, lenalidomide, temsirolimus, and bortezomib to
chemoimmunotherapy may be appropriate for some
patients, though careful attention for potential unex-
pected toxicity is important during initial assessments.
These combinations are being examined in multiple
phase II studies (Table 3) [71–80] some of which are
described in detail below.
Two studies have evaluated the combination of rit-
uximab, lenalidomide, and bendamustine (R2-B) in
MCL [71,72]. A phase I/II study in patients age >65
years (n¼ 51) with untreated stage II–IV MCL assessed
induction with six cycles of R2-B followed by mainten-
ance with 7 cycles of single-agent lenalidomide.
Inclusion criteria allowed treatment with one cycle of
chemotherapy or radiation therapy. Because of a high
number of AEs (especially allergic and cutaneous reac-
tions) in the phase I dose escalation, the protocol was
amended to omit lenalidomide during the first cycle
and to include corticosteroids and Pneumocystis carinii
pneumonia prophylaxis in subsequent cycles. In the
combined phase I and II parts of the study, 74% com-
pleted the induction phase and 24% of patients com-
pleted the maintenance phase. Best responses were
80% ORR and 64% CR/CRu. At a median follow-up of
31 months, the PFS was 42 months and the 3-year OS
was 73%. Of concern, many patients had a grade 3–5
infection, including three patients with opportunistic
infections, and 16% had a second primary malignancy.
In a phase II study of second-line therapy, patients
responding to R2-B induction received R2 consolida-
tion, and those with CR or partial response (PR) were
then treated with lenalidomide maintenance [72]. In
elderly patients (median age 70 years), ORR was 79%
(55% CR) after consolidation, and 24-month PFS and
OS rates were 43 and 67%, respectively. Toxicities
were predominantly hematologic: grade 3/4 neutro-
penia (71% in induction/consolidation; 72% during
maintenance) and grade 3/4 thrombocytopenia (14%
in induction/consolidation; 7% during maintenance).
Thirty-six percentage of responding patients achieved
minimal residual disease (MRD) negativity in bone
marrow following induction and consolidation.
A multicenter phase Ib study of temsirolimus in
combination with rituximab-chemotherapy in patients
with relapsed/refractory MCL reported ORRs of 56, 42,
and 80% for the combination of temsirolimus with
R-CHOP, RFC (rituximab, fludarabine, cyclophospha-
mide), and R-DHA (rituximab, dexamethasone, and
high-dose cytarabine), respectively [73]. The combin-
ation of temsirolimus with BR produced a 94% ORR
(39% CR) and a median PFS of 22 months in a recent
phase I/II study [74]. In the full patient population,
which included nine patients with follicular lymphoma,
the most common grade 3/4 AEs were leukopenia
(32%), neutropenia (24%), and thrombocytopenia (21%).
Most evidence exists for chemotherapy regimens
combined with bortezomib. Based on encouraging first
line data [81], a multicenter, phase II study randomized
patients with relapsed MCL who had received one
treatment prior to CHOP or bortezomib (days 1 and 8)
plus CHOP [75]. The addition of bortezomib improved
ORR (83% versus 48%), CR rates (35% versus 22%),
median PFS (16.5 versus 8.1 months), and median OS
(35.6 versus 11.8 months). The difference in OS was
statistically significant (p¼ .01), although higher rates
of grade 3/4 neutropenia (30% versus. 20%) in the
bortezomib-CHOP arm translated into increased febrile
neutropenia (39% versus 17%).
In patients unwilling or unable to receive first-line
dose-intensive therapy, the combination RiBVD (rituxi-
mab, bendamustine, bortezomib, and dexamethasone;
no maintenance) in a phase II study of newly diag-
nosed MCL patients >65 years of age has also shown
notable efficacy (84% ORR with a 24-month PFS of
70% at a median follow-up of 52 months), but was
hampered by prominent infectious complications [80].
Molecular-based combinations
With the availability of novel agents and biologic ther-
apy, treatment of relapsed/refractory MCL has moved
toward a molecular-based approach rather than a
high-dose, intense chemotherapy strategy. In addition
to monotherapy as discussed above, several agents
have been evaluated in combination mostly with ritux-
imab (Table 4) [64,82–92].
Ibrutinib was combined with rituximab in a single-
center, phase II trial enrolling patients with relapsed/
refractory MCL [82]. An 88% ORR (44% CR) was
reported, with atrial fibrillation (12%) being the only
grade 3/4 AE occurring in more than one patient. One
on-study death (septic shock) may have been treat-
ment related. Recent report of the MCL6 PHILEMON
phase II study from the Nordic Lymphoma Group
showed that ibrutinib combined with R2 was active
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(83% ORR, 41% CR) and well tolerated in relapsed/
refractory MCL patients, and was associated with
molecular remission in approximately half of MRD-
evaluable patients [83]. The phase II AIM trial of ibruti-
nib and venetoclax in patients with relapsed or refrac-
tory MCL showed a 71% ORR (63% CR) at week 16,
along with 80% of complete responders with negative
bone marrow by flow cytometry [84]. The 8-month
PFS and OS were 74% and 81%, respectively. Although
most AEs were grade 1/2, 25% of patients had grade
3/4 neutropenia and tumor lysis syndrome occurred in
two patients requiring dose reduction of venetoclax
from a 50–20mg/day starting dose.
The feasibility of administering lenalidomide in
combination with rituximab (R2 regimen) was demon-
strated in a phase I/II study [64]. In the phase II por-
tion, R2 was given to MCL patients, producing an ORR
of 57% (36% CR), with a median PFS and OS of 11.1
and 24.3 months, respectively. Patients who subse-
quently underwent stem cell transplantation, achieved
a 100% CR. R2 was well tolerated, with the most com-
mon grade 3/4 toxicities being neutropenia (66%),
lymphopenia (36%), leukopenia (30%), and thrombo-
cytopenia (23%). Of note, a single-center phase II study
of R2 in rituximab-resistant MCL, with oral lenalido-
mide daily for 8 weeks followed by four weekly treat-
ments with rituximab, with lenalidomide treatment
continued during and after rituximab, reported a 55%
ORR, all CR/CRu, and a median PFS of 24.4 months.
The regimen was well tolerated, with the most com-
mon grade 3/4 AE being neutropenia [85]. Promising
early data have been reported with temsirolimus/ritux-
imab combinations [88].
The combination of rituximab with bortezomib was
evaluated in the BRIL06 study [89]. Patients with
relapsed/refractory MCL or marginal zone lymphoma
not eligible for high-dose chemotherapy with stem
cell transplant were treated with weekly bortezomib
and standard rituximab for 4 weeks followed by two
courses of four-weekly bortezomib alone. Among the
MCL patients, ORR was 64% and 5-year PFS was 17%.
Treatment options
Treatments for younger patients without
comorbidities
Nearly one-half of all MCL patients are younger (<65
years) with no comorbidities (i.e. fit) [93]. In first
relapse, the treatment goal in patients not receiving
upfront transplant (and who are primary refractory or
early relapsed patients) is to achieve the best possible
remission as a bridge to either autologous or allogeneic
transplant (Figure 1). For transplant-ineligible patients,
the objective is to obtain the best possible response
to treatment to induce long-lasting remission.
Patients with an early first relapse (i.e. within 1–2 years
after initial therapy) are considered high risk. In
this setting, the treatment of choice is chemoimmuno-
therapy, such as BR, FCR, R-BAC (bendamustine, rituxi-
mab, cytarabine), or targeted therapy, such as
ibrutinib. Patients with longer remission (i.e. relapse
>2 years after initial therapy) may be treated with a
high-dose cytarabine-containing regimen in combin-
ation with rituximab. Ongoing clinical trials are explor-
ing whether adding a molecular-based and
immunomodulator agents, such as ibrutinib, lenalido-
mide, temsirolimus, and bortezomib to these chemo-
immunotherapy regimens will improve outcome in
younger patients.
In second relapse (if allogeneic transplantation is
not an option), the goal is to achieve the best possible
remission with chemotherapy or molecular-based regi-
mens not used in first- or second-line therapy, as toler-
ated by the patient. Treatment options in this setting
include rituximab combined with ibrutinib, lenalido-
mide, temsirolimus, or bortezomib.
Disease control and palliation becomes the goal of
treatment for subsequent relapses. In this setting, the
selection of treatment depends on the reported effi-
cacy but with a greater emphasis on minimizing tox-
icity and ease of administration. Accordingly, the
highest unmet need among younger patients is better
treatments for third and later relapses. If no cross-
resistance has been demonstrated in earlier lines of
therapy, monotherapy agents (± rituximab) may be
considered for these patients.
Treatments for elderly fit patients
Approximately 40–50% of MCL patients are aged>65
years without significant comorbidities and are no lon-
ger candidates for transplantation. In first relapse, the
treatment goal is to achieve and maintain the best
response for the longest possible duration. The toxicity
of the treatment needs to be taken into consideration,
as these patients are generally not considered suitable
for transplantation. Treatment regimens for these
patients are generally similar to those for fit younger
patients, including cytarabine-containing chemoimmu-
notherapy (e.g. R-BAC) in early first relapse, with pos-
sible addition of a targeted agent for elderly patients
rather than allogeneic stem cell transplantation (SCT).
Although no maintenance therapies are currently
approved, clinical studies have explored the use of rit-
uximab and lenalidomide with favorable results
EU TREATMENT: MANTLE CELL LYMPHOMA 1823
[41,94]. For late first relapse, a conventional dosing
with chemoimmunotherapy with/without a targeted
agent is employed.
In contrast to younger patients, elderly patients in
second relapse are given targeted monotherapy (ibru-
tinib, lenalidomide, or temsirolimus) with/without rit-
uximab. Alternatively, experimental therapies in a
clinical study setting may be investigated. The highest
unmet need in elderly, fit patients is for better, more
active and tolerable treatment for second and third
relapse.
Treatments for frail patients with comorbidities
Approximately 10% of MCL patients, irrespective of
age, have significant comorbidities. In first relapse, the
treatment goal is disease control and palliation to pro-
vide the best quality of life. Treatment options are lim-
ited, and combination chemotherapy is typically
inappropriate. For patients in early relapse, low-dose
chemotherapy (e.g. dose-reduced BR of chlorambucil/
rituximab) or targeted monotherapy (ibrutinib,
lenalidomide, or temsirolimus) with/without rituximab
are considered. For patients with later relapse, the lat-
ter molecular-based monotherapy with/without rituxi-
mab may be more appropriate.
Conclusions
Although clinical guidelines for treatment of relapsed/
refractory MCL are available in the EU and US, evi-
dence supporting specific treatment options requires
continued investigation. Most clinical trials in relapsed/
refractory MCL are small, non-randomized, phase II
studies conducted at a single center, or limited num-
bers of sites. In many cases, MCL was included as one
of multiple NHL subtypes evaluated. Few phase III
studies were completed in relapsed/refractory MCL.
Clearly, more clinical studies of this type are needed
to investigate promising phase II findings more rigor-
ously and to determine whether rationally designed
combination regimens offer improved efficacy and
safety compared with monotherapy.
Figure 1. Overview of treatment options in relapsed/refractory MCL based on patient age and fitness. allo: allogeneic; Ara-C: cytar-
abine; BR: bendamustineþ rituximab; CIT: chemoimmunotherapy; clb: chlorambucil; MCL: mantle cell lymphoma; R-BAC: rituximab,
bendamustine, cytarabine (Ara-C); SCT: stem cell transplantation.
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Combination regimens have generally provided
higher response rates than single agents but often
cause increased toxicity, making them difficult to use
in elderly, frail, or heavily pre-treated patients. The
addition of rituximab to other treatments has generally
proven beneficial to patient outcome. However, many
patients are not eligible for combination chemother-
apy regimens, typically those with significant comor-
bidities or a life expectancy less than 6 months;
younger, fit patients in third relapse; elderly, fit
patients in second relapse; and patients with chemo-
therapy-refractory disease. For such patients, mono-
therapy with newer molecular-based agents, such as
ibrutinib, lenalidomide, temsirolimus, and bortezomib
represent an appropriate treatment choice. These
agents can also be combined with rituximab or ste-
roids based on promising responses in multiple clinical
trials. Oral agents may be preferred in this setting as
patients can be treated at home. Thus, despite consid-
erable advances, a high unmet need for effective treat-
ments remains, particularly in the elderly and frail
patient populations.
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